Rockwell Medical, INC

Rockwell Medical announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Rockwell Medical, Inc. announced a one-for-ten reverse stock split of its common stock, effective July 1, 2026, to adjust its outstanding shares.

Rockwell Medical, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors, advisory vote on executive compensation, ratification of auditors, and approval of a reverse stock split.

Rockwell Medical has been notified by Nasdaq that its common stock failed to maintain the minimum $1.00 bid price requirement.

Rockwell Medical, Inc. has released an updated corporate presentation on May 7, 2026, detailing its current business status and strategic direction.

Rockwell Medical reported $17.3 million in net sales and $2.9 million in gross profit for Q1 2026, announcing operational changes expected to boost annualized gross profit by over $3 million.

Rockwell Medical, Inc. reported a net sales decrease of 8% for the first quarter of 2026 compared to the prior year, primarily driven by reduced sales to DaVita.

Rockwell Medical experienced a significant drop in net sales and shifted to a net loss for Q3 and the first nine months of 2025, primarily due to reduced DaVita purchases.

Rockwell Medical, Inc. reported a significant decline in net sales and a widened net loss for the second quarter and first half of 2025, primarily due to a major customer transitioning to a new supplier.

Rockwell Medical's Q1 2025 revenue decreased due to a major customer transitioning to another supplier, despite price adjustments and new distribution agreements.

Rockwell Medical's Q3 2024 results show a significant increase in revenue and a return to profitability, driven by strong product sales and a large premium-priced order.

Rockwell Medical saw a significant increase in net sales and gross profit in the second quarter of 2024, driven by new customer acquisitions and price increases.

Rockwell Medical reports a significant net sales decrease in 2025, primarily due to reduced DaVita purchases, while extending its product purchase agreement with DaVita through 2026 and focusing on new customer growth.

Rockwell Medical's 2024 10-K filing reveals a mixed outlook, with revenue growth offset by the impending loss of a major customer, balanced by new supply agreements and a focus on long-term growth strategies.

Rockwell Medical's 2023 annual report reveals a year of strategic growth, marked by key acquisitions, new partnerships, and increased revenue, while navigating a challenging economic landscape.

Joseph H. Dawson, a Director at Rockwell Medical, Inc., reported transactions involving restricted stock units and a reverse stock split.

Rockwell Medical, Inc. Director Allen Nissenson reported a change in beneficial ownership of common stock, reflecting a 1-for-10 reverse stock split.

Director Joan Lau of Rockwell Medical, Inc. (RMTI) reported a transaction involving common stock, including adjustments for a recent reverse stock split.

Rockwell Medical Director Robert S. Radie acquired 9,633 shares of common stock following a 1-for-10 reverse stock split, increasing his beneficial ownership.

John G. Cooper, a Director at Rockwell Medical, Inc., acquired 9,633 shares of common stock following a 1-for-10 reverse stock split.

Timothy Chole, SVP and CCO of Rockwell Medical, Inc., reported a transaction involving 15,000 shares of common stock on July 1, 2026, following a 1-for-10 reverse stock split.

Rockwell Medical, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for June 12, 2026, which will include proposals for director elections, executive compensation approval, auditor ratification, and a reverse stock split.

Rockwell Medical is holding its 2025 Annual Meeting of Stockholders virtually on May 20, 2025, to vote on director elections, executive compensation, auditor ratification, and an amendment to the long-term incentive plan.

Rockwell Medical will hold its 2024 Annual Meeting of Stockholders virtually on May 21, 2024, to vote on director elections, executive compensation, and auditor ratification.

Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Rockwell Medical, Inc., holding 1,808,309 shares of common stock.

Armistice Capital, LLC and Steven Boyd have disclosed a 6.29% beneficial ownership stake in Rockwell Medical, Inc., holding 2,149,471 shares of common stock as of June 30, 2025.

Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a reduced beneficial ownership of 4.99% of Rockwell Medical, Inc.'s common stock as of March 31, 2025.

Armistice Capital, LLC and Steven Boyd have disclosed a beneficial ownership of 9.99% of Rockwell Medical, Inc.'s common stock as of December 31, 2024.